TECX — Tectonic Therapeutic, Inc.

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and r… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$29.99
Market Cap$528M
Float11.2M
Shares Outstanding18.9M
vs. Analyst Target+159.7% to analyst PT
Dividend RateNone
Analyst Target Price$77.89 (6 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$120M -$1.2M -$119M
2021 N/A -$8.9M -$1.4M -$8.1M
2022 N/A -$32.2M -$4.2M -$31.0M
2023 N/A -$42.8M -$617,000 -$41.2M
2024 N/A -$58.0M -$1.6M -$56.2M
2025 N/A -$74.2M N/A -$71.5M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$20.0M
Sep 2025 N/A -$19.0M
Dec 2025 N/A -$19.2M
Mar 2026 N/A -$25.2M

Ownership & Float

Insider Ownership39.3%
Institutional Ownership74.1%
Short Float21.8%
% of All Funds Holding1.23%
Number of Funds Holding101

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$29.37Near-term / short-term trend
Weekly40-Week SMA$22.94Medium-term trend
Weekly80-Week SMA$26.17Cyclical trend (business cycle)
Weekly200-Week SMA$19.99Secular trend (multi-year)
Monthly10-Month SMA$23.41Near-term monthly trend
Monthly20-Month SMA$27.63Medium-term monthly trend
Monthly40-Month SMA$22.17Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$20.00 support 1.47x 2 months ago
$18.20 support 1.20x 5 months ago
$15.50 support 2.03x 6 months ago
$54.00 resistance 2.26x 14 months ago
$14.60 support 1.04x 23 months ago

Historical Earnings Reactions (32 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -3.32% -0.10% 43.75% 3.97% -91.67%
1 Day -2.52% -1.26% 40.63% 10.11% -91.67%
1 Week 0.60% -0.07% 46.88% 49.90% -23.46%
2 Weeks 3.18% 1.36% 53.13% 81.54% -29.58%
1 Month -0.12% -1.72% 41.94% 69.23% -54.48%

Next earnings: July 26, 2026 (60 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-3.8%50.0%8
Feb-0.5%50.0%8
Mar-1.2%37.5%8
Apr-8.6%12.5%8
May7.5%71.4%7
Jun-4.8%14.3%7
Jul13.1%62.5%8
Aug2.1%62.5%8
Sep-3.7%37.5%8
Oct4.1%87.5%8
Nov2.5%50.0%8
Dec-5.0%50.0%8

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 2.63% 42.0% 374
Tuesday -0.73% 43.4% 410
Wednesday 0.75% 46.8% 406
Thursday 0.44% 47.6% 399
Friday -0.20% 44.9% 401

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 74.1%

Insider Transactions — Smart Summary

Total insider ownership: 39.3%

Founder-led management: Timothy A. Springer (Co-Founder & Independent Director)

12-Month Insider Activity Summary

Total Filings8
Net Value-$385,289.349
Net Shares Change15,089
% of Float0.1%
C-Suite Filings8
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Ruddy Marcella K. Chief Medical Officer -$363,000 3 N/A
McNamara Peter Chief Scientific Officer -$257,449.349 2 N/A
Lochner Daniel Chief Financial Officer +$129,660 1 1 buy
REICIN ALISE Chief Executive Officer +$105,500 2 2 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-03-05 – 2026-03-09 4 3 -$504,699.349 4 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-05 REICIN ALISE Chief Executive Officer +$52,750 Transaction at $21.10, now +42.1%
2026-02-11 Lochner Daniel Chief Financial Officer +$129,660 Transaction at $21.61, now +38.8%
2026-02-12 REICIN ALISE Chief Executive Officer +$52,750 Transaction at $21.10, now +42.1%
2026-03-09 Ruddy Marcella K. Chief Medical Officer -$300,000 Transaction at $30.00, now -0.0%
2026-03-05 McNamara Peter Chief Scientific Officer -$77,626.79 Transaction at $23.53, now +27.5%
2026-03-09 McNamara Peter Chief Scientific Officer -$179,822.559 Transaction at $16.76, now +78.9%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Tectonic Therapeutic, Inc. (TECX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for TECX on Trend Edge →